Novo Nordisk consumer marketing chief Mark Materacky wants to change the conversation around obesity. And with Wegovy, the first new anti-obesity med approval in a decade — with good efficacy and safety data — Novo seems well positioned to do that.
However, in the year and a half since its approval, Wegovy, or semaglutide for weight loss, a cascade of events has marred the way.
Type 2 diabetes meds, including semaglutide, marketed for diabetes treatment under the brand Ozempic, and tirzepatide, sold as Mounjaro by Eli Lilly, started getting picked up by new online telehealth companies, along with personal physicians who realized the meds could be prescribed off-label for obesity and weight loss.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.